肿瘤分子生物学研究室（张熠 教授）
张熠，苏州大学药理学系教授，药理学系副主任。主要从事肿瘤药理学的研究。迄今为止，在国内外权威期刊如Cancer Res、Oncogene、Autophagy、Molecular Cancer Therapy、J Biol Chem、Biochemical Pharmacology、Cancer Biology Therapy等发表论文20余篇，其中第一/通讯作者10余篇；获江苏省优秀博士论文，中美抗癌协会-亚洲癌症研究基金会（USCACA-AFCR）Scholar Award，中国药理学会-施维雅青年药理学家奖；江苏省高校“青蓝工程”优秀青年骨干教师培养对象；江苏省六大人才高峰。目前已申请中国发明专利5项，授权1项；现主持国家自然科学基金面上项目3项，江苏省自然科学基金面上项目，中国博士后特别资助项目；中国博士后一等资助项目；江苏省高校自然科学基金项目，苏州市医疗卫生科技项目；社会兼职：现任国家自然科学基金通讯评审专家，中国药理学会肾脏药理专业委员会委员，BioMed Research International杂志编委，《中华肿瘤防治杂志》青年编委。
E-mail Address:zhangyi@suda.edu.cn, yzhang25b@gmail.com.
Research Interests（研究方向）
（1）肿瘤的发生和恶化的机制
（2）抗肿瘤药物耐药性产生机理和信号传导通路变化
（3）肿瘤治疗新靶点的发现和新药研发
GRANT SUPPORT（主持课题基金）
1. 国家自然科学基金面上项目（项目编号：81973352）
2. 国家自然科学基金面上项目（项目编号：81773749）
3. 国家自然科学基金面上项目（项目编号：81473240）
4. 江苏省自然科学基金面上项目（项目编号：BK20141197）
5. 国家博士后特别资助项目（项目编号：2015T80585）
6. 国家博士后基金（一等）资助项目（项目编号：2014M550308）
7. 苏州市科技发展计划（应用基础研究∙医疗卫生，SYS201319）
8. 江苏省高校自然科学基金（12KJD310005）
9. 国家自然科学基金青年项目 （81101913/H1622)
10. 基石药业转化合作研究资助（2019-2021）
Publications（论文发表）
1. Lingchuan Guo, Weidong Zhu, Xiangyuan Ma, Hao Ni, Enjian Zhong, Yang W.Shao, Jie Yu, Dongmei Gu1, Shundong Ji, , Haodong Xu, Cheng Ji, Jinming Yang*, Yi Zhang*. Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer, Cancer Biol Ther, 2019;20(3):240-246.. *(Corresponding author)
2. Xiao-Hui Wang, Cheng Ji, Hong-Han Zhang, Yu Shan, Yi-Jie Ren, Yan-Wei Hu, Ling-Chuan Guo, Wei-Dong Zhu, Yu-Juan Xia1, Bei-Jia Liu, Zi-Yun Rong, Bi-Lian Wu, Zhi-Jun Ming, Jianxun Song, Jin-Ming Yang*, Yi Zhang*. Identification of a small-molecule compound that inhibits homodimerization of oncogenic NAC1 protein and sensitizes cancer cells to anticancer agents. J Biol Chem, 2019 Jun 21;294(25):10006-10017. *(Corresponding author)
3. Yu P, Wang HY, Tian M, Li AX, Chen XS, Wang XL, Zhang Y*, Cheng Y*. Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.Acta Pharmacol Sin. 2019 Mar 26. doi: 10.1038/s41401-019-0222-z. *(Corresponding author)
4. Cheng Ji, Qiong-Hua Xu, Ling-Chuan Guo, Yi-Jie Ren, Hong-Han Zhang, Wei-Dong Zhu, Zhi-Jun Ming, Yun-Sheng Yuan, Xin-Cong Ren, Yan Cheng, Jin-Ming Yang*, Yi Zhang*. eEF-2 Kinase-targeted miR-449b Confers Radiation Sensitivity to Cancer Cells, Cancer Lett, 2018, Apr 1;418:64-74. *(Corresponding author)
5. Yi Zhang*, Yi-Jie Ren, Ling-Chuan Guo, Cheng Ji, Jian Hu, Hong-Han Zhang,Qiong-Hua Xu, Wei-Dong Zhu, Zhi-Jun Ming, Yun-Sheng Yuan, Xingcong Ren, Jianxun, Song, and Jin-Ming Yang*. Nucleus Accumbens-Associated Protein-1 Promotes Glycolysis and Survival of Hypoxic Tumor Cells via the HDAC4-HIF-1α Axis, Oncogene, 2017 Jul 20;36(29):4171-4181. *(Corresponding author) Evaluated in“F1000” by“Faculty Of 1000 Biology”
6. Yi-Jie Ren, Xiao-Hui Wang, Cheng Ji, Yi-Di Guan, Xian-Jiu Lu, Xian-Rong Liu,Hong-Han Zhang, Ling-Chuan Guo, Qiong-Hua Xu, Wei-Dong Zhu, Zhi-Jun Ming, Jin-Ming Yang, Yan Cheng, Yi Zhang*. Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol, Front. Pharmacol, 07 November 2017,00804.
7. Zhang Y*, Yang WQ, Zhu H, Zhou L, Ren YJ, Ren XC, Zhang L, Wang JR, Liu YB, Yang JM. Regulation of Autophagy by miR-30d Impacts Sensitivity of Anaplastic Thyroid Carcinoma to Cisplatin, Biochem Pharmacol,2014 Feb 15;87(4):562-70. *(Corresponding author)
8. Ren YJ, Zhang Y*. An update on RNA interference-mediated gene silencing in cancer therapy. Expert Opin Biol Ther, 2014 Nov;14(11):1581-92. *(Corresponding author)
9. Xiao-yuan Liu, Li Zhang, JianPing Wu, Lei Zhou, Yi-Jie Ren, Wei-Qiong Yang, Zi-Jun Ming, Bo Chen, Jianrong Wang, Yi Zhang* and Jin-Ming Yang*. Inhibition of Elongation Factor-2 Kinase Augments the Antitumor Activity of Temozolomide against Glioma. PLoS One,2013 Nov 26;8(11):e81345. *(Corresponding author)
10. Zhang Y*, Yang JM*. Altered energy metabolism in cancer: An unique opportunity for therapeutic intervention. Cancer Biol Ther,2013 Feb 1; 14(2):81-9. (*Corresponding author)
11. Zhang Y, Cheng Y, Ren XC, Hori T, Huber-KeenerKJ, Zhang L, Yap KL, Liu D, Shantz L, Qin ZH, Zhang SP, Wang JR, Wang HG, Shih IM and Yang JM: Dysfunction of Nucleus Accumbens-1 Activates Cellular Senescence and Inhibits Tumor Cell Proliferation and Oncogenesis. Cancer Res,72(16): 4262-4275, 2012.
12. Zhang Y, Cheng Y, Ren XC, Zhang L, Yap KL, Wu H, Patel R, Liu DX, Qin ZH, Shih IM and Yang JM*: NAC1 Modulates Sensitivity of Ovarian Cancer Cells to Cisplatin via Altering the HMGB1-Mediated Autophagic Response. Oncogene, 31(8): 1055-1064, 2012.
13. Yang WQ, Zhang Y*. RNAi-mediated gene silencing in cancer therapy. Expert Opin Biol Ther, 2012 Nov; 12(11):1495-504. (Invited Review, *Corresponding author)
14. Zhang Y, Jay W. Yang, Xingcong Ren and Jin-Ming Yang. NAC1 and HMGB1 enter a partnership for manipulating autophagy. Autophagy,2011 Dec 1;7(12).
15. Zhang Y*, Cheng Y, Zhang L, Ren X, Huber-Keener KJ, Lee S, Yun J, Wang HG, Yang JM. Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression. Biochem Biophys Res Commun,2011 Oct 14; 414(1):129-34. (* Corresponding author)
16. Zhang Y#, Zhang L#, Liu XY, Qin ZH, Yang JM. Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells. Acta Pharmacol Sin,2011, Mar;32(3):361-7. (# contributed equally to this study)
17. Zhang Y*, Yang JM. The impact of cellular senescence in cancer therapy: is it true or not? Acta Pharmacol Sin,2011 Oct; 32(10):1199-207. (* Corresponding author)
18. Li Z, Wang Y, Fu C, Wang X, Wang JJ, Zhang Y, Zhou D, Zhao Y, Luo L, Ma H, Lu W, Zheng J, Zhang X. Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists. Eur J Med Chem, 2018 Apr 10;149:30-44.
19. Cheng Y, Ren X, Zhang Y, Shan Y, Huber-Keener KJ, Zhang L, Kimball SR, Harvey H, Jefferson LS, Yang JM. Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells. Autophagy, 2013 Feb 1;9(2):208-19.
20. Yan Cheng, Ugir Hossain Sk, Yi Zhang, Xingcong Ren, Li Zhang, Kathryn J. Huber-Keener, Yuan-Wan Sun, Jason Liao, Shantu Amin, Arun K. Sharma, and Jin-Ming Yang. Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. PLoS One, 2012;7(4):e35104.
21. Cheng Y, Zhang Y, Zhang L, Ren XC, Huber-Keener KJ, Liu XY, Zhou L, Liao J, Keihack H, Yan L, Rubin E, Yang JM. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther, 2012 Jan;11(1):154-64.
22. Cheng Y, Ren X, Zhang Y, Patel R, Sharma A, Wu H, Robertson GP, Yan L, Rubin E, Yang JM. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res, 2011 Apr 1;71(7):2654-63.
23. Zhang L, Ren XC, Cheng Y, Huber-Keener KJ, Liu XP, Zhang Y, Yuan YS, Yang J, Liu CG, Yang JM: Identification of Sirtuin 3, a Mitochondrial Protein Deacetylase, as a New Contributor to Tamoxifen Resistance in Breast Cancer Cells. Biochem Pharmacol, 86(6): 726-733, 2013.
24. Shan Y, Cheng Y, Zhang Y, Guan FQ, Sun H, Ren XC, Chen Y, Feng X, Yang JM: Triticuside A, a Dietary Flavonoid, Inhibits Proliferation of Human Breast Cancer Cells via Inducing Apoptosis. Nutr Cancer, 65(6): 891-899, 2013.
25. Huber-Keener KJ, Liu X, Wang Z, Wang YQ, Freeman W, Wu S, Planas-Silva MD, Ren XC, Cheng Y, Zhang Y, Vrana K, Liu CG, Yang JM and Wu RL: Differential Gene Expression in Tamoxifen-resistant Breast Cancer Cells Revealed by a New Analytical Model of RNA-Seq Data. PLoS One,7(7): e41333, 2012
26. Huber-Keener KJ, Evans BR, Ren X, Cheng Y, Zhang Y, Hait WN, Yang JM: Phosphorylation of Elongation Factor-2 Kinase Differentially Regulates the Enzyme's Stability under Stress Conditions. Biochem Biophys Res Commun, 424(2): 308-14, 2012.
版权所有:Copyright © 2022 All Rights Reserved 苏州大学苏州医学院药学院
地址：苏州市工业园区仁爱路199号苏州大学独墅湖校区二期云轩楼
